Sprout Health Review: $149 Is One Coupon, Then $299 Every Four Weeks

$299 every four weeks for compounded semaglutide and $349 every four weeks for compounded tirzepatide. The $149 and $199 on the homepage are those prices with a one-time $150 coupon, FIRST150, applied to a first order — Sprout's own funnel FAQ says it in a sentence: "The program costs $299/month for Compounded Semaglutide and $349/month for Compounded Tirzepatide. Get $150 off your first month with code: FIRST150." Applying that code to the semaglutide product on August 9, 2026 returned a $150.00 discount and a $149.00 total, so the arithmetic is not in dispute — only the presentation is.

Because Sprout does not bill monthly. Its catalogue prices the plan as "$299.00 every 4 weeks", and the checkout, loaded on August 9, 2026, scheduled the first renewal for September 6 — twenty-eight days later, not a calendar month. Four-weekly billing means thirteen charges a year rather than twelve. Semaglutide is therefore $3,887 a year, not $3,588, and tirzepatide is $4,537 rather than $4,188. The extra charge is worth roughly one free month to Sprout and is invisible in the phrase "per month", which is exactly why it is worth checking on any provider that uses it.

The consultation, the follow-ups, the injection kit and the shipping, and Sprout commits to that in its Terms rather than in marketing copy: §31 reads, "All prices displayed at checkout are comprehensive and include the fees for the mandatory doctor consultation." The checkout backs it — subtotal $299.00, total $299.00, with no service fee, platform fee or consultation line of the kind that turns a $299 headline into a $340 charge elsewhere in this category. The funnel FAQ adds follow-up appointments, clinician messaging, a four-week supply and shipping, with the phrase "NO hidden fees".

No, and Sprout puts it in writing: "One-time discounts not withstanding, the price stated upon your initial subscription will always be honored, even if your dosage increases and more vials are needed in subsequent months." This is the single most valuable sentence on the site. Semaglutide and tirzepatide are titration drugs — you climb from a starting dose over months — and most sellers re-price at each step, which means a quote taken at 0.25 mg tells you very little about what month six costs. Sprout's does not move, so the $3,887 and $4,537 annual figures hold at any dose.

It depends entirely on how far the order has travelled, and Sprout's Refund and Returns Policy sets out three stages plainly. Before a licensed provider has reviewed your intake, you get a complete refund, "no questions asked". After the review but before the prescription is sent to the pharmacy, you get a refund minus a flat $50 clinical review fee, which is the real cost of finding out whether Sprout will prescribe for you at all. Once the prescription reaches the pharmacy, nothing is refundable — standard for dispensed prescriptions. Package problems have a hard window: photographs of the box, label, ice packs and medication, emailed within 24 hours of delivery.

Its own documents do not agree, so check before you pay. Sprout's Terms §30 says: "Our services are available to patients in all U.S. states, except: AL, AR, MS, LA, CA, ND", and then lists 44 states by abbreviation. Its weight-loss funnel page advertises "5000+ patients in 50 states". And the checkout's state selector offers all fifty plus the District of Columbia with no restriction at all — including California, which is both on the exclusion list and the location of Sprout's own listed office in Encinitas. A checkout that accepts your address is not the same as a provider licensed to treat you in your state, and here the narrower claim is the one the company made in its Terms. If you are in one of those six, email before ordering rather than relying on the form letting you through.

On September 9, 2025 FDA's Center for Drug Evaluation and Research wrote to Sprout Health Partners LLC about joinsprouthealth.com, and the letter is unusually narrow: it quotes one sentence from the site — "GLP-1 medications are FDA-approved and backed by extensive clinical research…." — and answers it in one line: "Compounded drug products are not FDA-approved. Your claim implies that your products are the same as an FDA-approved product when they are not." That makes the products misbranded under sections 502(a) and 502(bb). Nothing in it concerns sterility, potency, contamination or either pharmacy, and the only action demanded is to stop using that language. The index headline on the letter is much broader than its contents, which is worth knowing before reading any letter in this enforcement wave. The sentence is gone: every page in Sprout's current sitemap was checked on August 9, 2026 and none carries it. FDA has recorded no close-out, so the letter is still formally open.

Yes, and by less than the labels suggest, because they are billed in different units. The three-month semaglutide plan bills $615.00 every 12 weeks, which is $205 per four-week cycle rather than $299 — about a 31% saving, and the same block for tirzepatide is $750.00 every 12 weeks, or $250 a cycle. The six-month plans are $1,014.00 and $1,374.00 and, unlike the shorter ones, renew every six calendar months rather than on a multiple of four weeks. What you give up is the exit: the $50-review-fee escape hatch applies to the order you have placed, so a six-month block commits you to six months of medication the moment the prescription is written. On a drug a meaningful number of people stop within the first two months because of side effects, that is the trade to think about rather than the headline discount.

Sprout names them, which is rarer in this category than it should be. Its Terms list MD Integrations, described as a physician-only clinical network, as the source of the licensed providers, and Foothills Pharmacy and Promise Pharmacy as the dispensing pharmacies, each with a contact address. That matters for two reasons: it lets you check the pharmacy's licensure yourself instead of taking "a licensed US pharmacy" on trust, and it means the compounding is done by a named third party rather than by Sprout, which is not a pharmacy. Neither pharmacy holds an FDA warning letter — both were screened on August 9, 2026 and returned nothing.